

# Global Anti-spasmodic Drugs Market 2024 by Company, Regions, Type and Application, Forecast to 2030

<https://marketpublishers.com/r/G604324FEF85EN.html>

Date: July 2024

Pages: 128

Price: US\$ 3,480.00 (Single User License)

ID: G604324FEF85EN

## Abstracts

According to our (Global Info Research) latest study, the global Anti-spasmodic Drugs market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.

Antispasmodic drugs such as dicyclomine (Bentyl) and hyoscyamine (Levsin) relieve the stomach cramps brought on by IBS by relaxing the smooth muscle of the gut. They also may cause constipation, so they aren't usually prescribed for people who suffer from IBS-C. Other side effects are dry mouth, drowsiness, and blurred vision.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

The Global Info Research report includes an overview of the development of the Anti-spasmodic Drugs industry chain, the market status of Offline Channel (Antimuscarinics, Smooth Muscle Relaxants), Online Channel (Antimuscarinics, Smooth Muscle Relaxants), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Anti-spasmodic Drugs.

Regionally, the report analyzes the Anti-spasmodic Drugs markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Anti-spasmodic Drugs market, with robust domestic demand, supportive policies, and a strong manufacturing base.

#### Key Features:

The report presents comprehensive understanding of the Anti-spasmodic Drugs market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Anti-spasmodic Drugs industry.

The report involves analyzing the market at a macro level:

**Market Sizing and Segmentation:** Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Antimuscarinics, Smooth Muscle Relaxants).

**Industry Analysis:** Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Anti-spasmodic Drugs market.

**Regional Analysis:** The report involves examining the Anti-spasmodic Drugs market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

**Market Projections:** Report covers the gathered data and analysis to make future projections and forecasts for the Anti-spasmodic Drugs market. This may include estimating market growth rates, predicting market demand, and identifying emerging

trends.

The report also involves a more granular approach to Anti-spasmodic Drugs:

**Company Analysis:** Report covers individual Anti-spasmodic Drugs players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

**Consumer Analysis:** Report covers data on consumer behaviour, preferences, and attitudes towards Anti-spasmodic Drugs. This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Offline Channel, Online Channel).

**Technology Analysis:** Report covers specific technologies relevant to Anti-spasmodic Drugs. It assesses the current state, advancements, and potential future developments in Anti-spasmodic Drugs areas.

**Competitive Landscape:** By analyzing individual companies, suppliers, and consumers, the report presents insights into the competitive landscape of the Anti-spasmodic Drugs market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

**Market Validation:** The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

## Market Segmentation

Anti-spasmodic Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.

### Market segment by Type

Antimuscarinics

Smooth Muscle Relaxants

### Market segment by Application

Offline Channel

Online Channel

Market segment by players, this report covers

Pfizer

Allergan

Ipsen

Teva Pharmaceuticals

Novartis

Johnson & Johnson

Takeda Pharmaceutical

Sun Pharmaceutical Industries

Merz Pharma

Mylan

Fresenius Kabi

Endo International

Daewoong Pharmaceutical

Acorda Therapeutics

SteriMax

Emcure Pharmaceuticals

Sawai Pharmaceutical

Orient Pharma

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)

South America (Brazil, Argentina and Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Anti-spasmodic Drugs product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Anti-spasmodic Drugs, with revenue, gross margin and global market share of Anti-spasmodic Drugs from 2019 to 2024.

Chapter 3, the Anti-spasmodic Drugs competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024. and Anti-spasmodic Drugs market forecast, by regions, type and application, with consumption value, from 2025 to 2030.

Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces

analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Anti-spasmodic Drugs.

Chapter 13, to describe Anti-spasmodic Drugs research findings and conclusion.

## Contents

### 1 MARKET OVERVIEW

- 1.1 Product Overview and Scope of Anti-spasmodic Drugs
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Classification of Anti-spasmodic Drugs by Type
  - 1.3.1 Overview: Global Anti-spasmodic Drugs Market Size by Type: 2019 Versus 2023 Versus 2030
  - 1.3.2 Global Anti-spasmodic Drugs Consumption Value Market Share by Type in 2023
  - 1.3.3 Antimuscarinics
  - 1.3.4 Smooth Muscle Relaxants
- 1.4 Global Anti-spasmodic Drugs Market by Application
  - 1.4.1 Overview: Global Anti-spasmodic Drugs Market Size by Application: 2019 Versus 2023 Versus 2030
  - 1.4.2 Offline Channel
  - 1.4.3 Online Channel
- 1.5 Global Anti-spasmodic Drugs Market Size & Forecast
- 1.6 Global Anti-spasmodic Drugs Market Size and Forecast by Region
  - 1.6.1 Global Anti-spasmodic Drugs Market Size by Region: 2019 VS 2023 VS 2030
  - 1.6.2 Global Anti-spasmodic Drugs Market Size by Region, (2019-2030)
  - 1.6.3 North America Anti-spasmodic Drugs Market Size and Prospect (2019-2030)
  - 1.6.4 Europe Anti-spasmodic Drugs Market Size and Prospect (2019-2030)
  - 1.6.5 Asia-Pacific Anti-spasmodic Drugs Market Size and Prospect (2019-2030)
  - 1.6.6 South America Anti-spasmodic Drugs Market Size and Prospect (2019-2030)
  - 1.6.7 Middle East and Africa Anti-spasmodic Drugs Market Size and Prospect (2019-2030)

### 2 COMPANY PROFILES

- 2.1 Pfizer
  - 2.1.1 Pfizer Details
  - 2.1.2 Pfizer Major Business
  - 2.1.3 Pfizer Anti-spasmodic Drugs Product and Solutions
  - 2.1.4 Pfizer Anti-spasmodic Drugs Revenue, Gross Margin and Market Share (2019-2024)
  - 2.1.5 Pfizer Recent Developments and Future Plans
- 2.2 Allergan
  - 2.2.1 Allergan Details

- 2.2.2 Allergan Major Business
- 2.2.3 Allergan Anti-spasmodic Drugs Product and Solutions
- 2.2.4 Allergan Anti-spasmodic Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 2.2.5 Allergan Recent Developments and Future Plans
- 2.3 Ipsen
  - 2.3.1 Ipsen Details
  - 2.3.2 Ipsen Major Business
  - 2.3.3 Ipsen Anti-spasmodic Drugs Product and Solutions
  - 2.3.4 Ipsen Anti-spasmodic Drugs Revenue, Gross Margin and Market Share (2019-2024)
  - 2.3.5 Ipsen Recent Developments and Future Plans
- 2.4 Teva Pharmaceuticals
  - 2.4.1 Teva Pharmaceuticals Details
  - 2.4.2 Teva Pharmaceuticals Major Business
  - 2.4.3 Teva Pharmaceuticals Anti-spasmodic Drugs Product and Solutions
  - 2.4.4 Teva Pharmaceuticals Anti-spasmodic Drugs Revenue, Gross Margin and Market Share (2019-2024)
  - 2.4.5 Teva Pharmaceuticals Recent Developments and Future Plans
- 2.5 Novartis
  - 2.5.1 Novartis Details
  - 2.5.2 Novartis Major Business
  - 2.5.3 Novartis Anti-spasmodic Drugs Product and Solutions
  - 2.5.4 Novartis Anti-spasmodic Drugs Revenue, Gross Margin and Market Share (2019-2024)
  - 2.5.5 Novartis Recent Developments and Future Plans
- 2.6 Johnson & Johnson
  - 2.6.1 Johnson & Johnson Details
  - 2.6.2 Johnson & Johnson Major Business
  - 2.6.3 Johnson & Johnson Anti-spasmodic Drugs Product and Solutions
  - 2.6.4 Johnson & Johnson Anti-spasmodic Drugs Revenue, Gross Margin and Market Share (2019-2024)
  - 2.6.5 Johnson & Johnson Recent Developments and Future Plans
- 2.7 Takeda Pharmaceutical
  - 2.7.1 Takeda Pharmaceutical Details
  - 2.7.2 Takeda Pharmaceutical Major Business
  - 2.7.3 Takeda Pharmaceutical Anti-spasmodic Drugs Product and Solutions
  - 2.7.4 Takeda Pharmaceutical Anti-spasmodic Drugs Revenue, Gross Margin and Market Share (2019-2024)



- 2.7.5 Takeda Pharmaceutical Recent Developments and Future Plans
- 2.8 Sun Pharmaceutical Industries
  - 2.8.1 Sun Pharmaceutical Industries Details
  - 2.8.2 Sun Pharmaceutical Industries Major Business
  - 2.8.3 Sun Pharmaceutical Industries Anti-spasmodic Drugs Product and Solutions
  - 2.8.4 Sun Pharmaceutical Industries Anti-spasmodic Drugs Revenue, Gross Margin and Market Share (2019-2024)
  - 2.8.5 Sun Pharmaceutical Industries Recent Developments and Future Plans
- 2.9 Merz Pharma
  - 2.9.1 Merz Pharma Details
  - 2.9.2 Merz Pharma Major Business
  - 2.9.3 Merz Pharma Anti-spasmodic Drugs Product and Solutions
  - 2.9.4 Merz Pharma Anti-spasmodic Drugs Revenue, Gross Margin and Market Share (2019-2024)
  - 2.9.5 Merz Pharma Recent Developments and Future Plans
- 2.10 Mylan
  - 2.10.1 Mylan Details
  - 2.10.2 Mylan Major Business
  - 2.10.3 Mylan Anti-spasmodic Drugs Product and Solutions
  - 2.10.4 Mylan Anti-spasmodic Drugs Revenue, Gross Margin and Market Share (2019-2024)
  - 2.10.5 Mylan Recent Developments and Future Plans
- 2.11 Fresenius Kabi
  - 2.11.1 Fresenius Kabi Details
  - 2.11.2 Fresenius Kabi Major Business
  - 2.11.3 Fresenius Kabi Anti-spasmodic Drugs Product and Solutions
  - 2.11.4 Fresenius Kabi Anti-spasmodic Drugs Revenue, Gross Margin and Market Share (2019-2024)
  - 2.11.5 Fresenius Kabi Recent Developments and Future Plans
- 2.12 Endo International
  - 2.12.1 Endo International Details
  - 2.12.2 Endo International Major Business
  - 2.12.3 Endo International Anti-spasmodic Drugs Product and Solutions
  - 2.12.4 Endo International Anti-spasmodic Drugs Revenue, Gross Margin and Market Share (2019-2024)
  - 2.12.5 Endo International Recent Developments and Future Plans
- 2.13 Daewoong Pharmaceutical
  - 2.13.1 Daewoong Pharmaceutical Details
  - 2.13.2 Daewoong Pharmaceutical Major Business

- 2.13.3 Daewoong Pharmaceutical Anti-spasmodic Drugs Product and Solutions
- 2.13.4 Daewoong Pharmaceutical Anti-spasmodic Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 2.13.5 Daewoong Pharmaceutical Recent Developments and Future Plans
- 2.14 Acorda Therapeutics
  - 2.14.1 Acorda Therapeutics Details
  - 2.14.2 Acorda Therapeutics Major Business
  - 2.14.3 Acorda Therapeutics Anti-spasmodic Drugs Product and Solutions
  - 2.14.4 Acorda Therapeutics Anti-spasmodic Drugs Revenue, Gross Margin and Market Share (2019-2024)
  - 2.14.5 Acorda Therapeutics Recent Developments and Future Plans
- 2.15 SteriMax
  - 2.15.1 SteriMax Details
  - 2.15.2 SteriMax Major Business
  - 2.15.3 SteriMax Anti-spasmodic Drugs Product and Solutions
  - 2.15.4 SteriMax Anti-spasmodic Drugs Revenue, Gross Margin and Market Share (2019-2024)
  - 2.15.5 SteriMax Recent Developments and Future Plans
- 2.16 Emcure Pharmaceuticals
  - 2.16.1 Emcure Pharmaceuticals Details
  - 2.16.2 Emcure Pharmaceuticals Major Business
  - 2.16.3 Emcure Pharmaceuticals Anti-spasmodic Drugs Product and Solutions
  - 2.16.4 Emcure Pharmaceuticals Anti-spasmodic Drugs Revenue, Gross Margin and Market Share (2019-2024)
  - 2.16.5 Emcure Pharmaceuticals Recent Developments and Future Plans
- 2.17 Sawai Pharmaceutical
  - 2.17.1 Sawai Pharmaceutical Details
  - 2.17.2 Sawai Pharmaceutical Major Business
  - 2.17.3 Sawai Pharmaceutical Anti-spasmodic Drugs Product and Solutions
  - 2.17.4 Sawai Pharmaceutical Anti-spasmodic Drugs Revenue, Gross Margin and Market Share (2019-2024)
  - 2.17.5 Sawai Pharmaceutical Recent Developments and Future Plans
- 2.18 Orient Pharma
  - 2.18.1 Orient Pharma Details
  - 2.18.2 Orient Pharma Major Business
  - 2.18.3 Orient Pharma Anti-spasmodic Drugs Product and Solutions
  - 2.18.4 Orient Pharma Anti-spasmodic Drugs Revenue, Gross Margin and Market Share (2019-2024)
  - 2.18.5 Orient Pharma Recent Developments and Future Plans

### **3 MARKET COMPETITION, BY PLAYERS**

3.1 Global Anti-spasmodic Drugs Revenue and Share by Players (2019-2024)

3.2 Market Share Analysis (2023)

3.2.1 Market Share of Anti-spasmodic Drugs by Company Revenue

3.2.2 Top 3 Anti-spasmodic Drugs Players Market Share in 2023

3.2.3 Top 6 Anti-spasmodic Drugs Players Market Share in 2023

3.3 Anti-spasmodic Drugs Market: Overall Company Footprint Analysis

3.3.1 Anti-spasmodic Drugs Market: Region Footprint

3.3.2 Anti-spasmodic Drugs Market: Company Product Type Footprint

3.3.3 Anti-spasmodic Drugs Market: Company Product Application Footprint

3.4 New Market Entrants and Barriers to Market Entry

3.5 Mergers, Acquisition, Agreements, and Collaborations

### **4 MARKET SIZE SEGMENT BY TYPE**

4.1 Global Anti-spasmodic Drugs Consumption Value and Market Share by Type (2019-2024)

4.2 Global Anti-spasmodic Drugs Market Forecast by Type (2025-2030)

### **5 MARKET SIZE SEGMENT BY APPLICATION**

5.1 Global Anti-spasmodic Drugs Consumption Value Market Share by Application (2019-2024)

5.2 Global Anti-spasmodic Drugs Market Forecast by Application (2025-2030)

### **6 NORTH AMERICA**

6.1 North America Anti-spasmodic Drugs Consumption Value by Type (2019-2030)

6.2 North America Anti-spasmodic Drugs Consumption Value by Application (2019-2030)

6.3 North America Anti-spasmodic Drugs Market Size by Country

6.3.1 North America Anti-spasmodic Drugs Consumption Value by Country (2019-2030)

6.3.2 United States Anti-spasmodic Drugs Market Size and Forecast (2019-2030)

6.3.3 Canada Anti-spasmodic Drugs Market Size and Forecast (2019-2030)

6.3.4 Mexico Anti-spasmodic Drugs Market Size and Forecast (2019-2030)

## **7 EUROPE**

- 7.1 Europe Anti-spasmodic Drugs Consumption Value by Type (2019-2030)
- 7.2 Europe Anti-spasmodic Drugs Consumption Value by Application (2019-2030)
- 7.3 Europe Anti-spasmodic Drugs Market Size by Country
  - 7.3.1 Europe Anti-spasmodic Drugs Consumption Value by Country (2019-2030)
  - 7.3.2 Germany Anti-spasmodic Drugs Market Size and Forecast (2019-2030)
  - 7.3.3 France Anti-spasmodic Drugs Market Size and Forecast (2019-2030)
  - 7.3.4 United Kingdom Anti-spasmodic Drugs Market Size and Forecast (2019-2030)
  - 7.3.5 Russia Anti-spasmodic Drugs Market Size and Forecast (2019-2030)
  - 7.3.6 Italy Anti-spasmodic Drugs Market Size and Forecast (2019-2030)

## **8 ASIA-PACIFIC**

- 8.1 Asia-Pacific Anti-spasmodic Drugs Consumption Value by Type (2019-2030)
- 8.2 Asia-Pacific Anti-spasmodic Drugs Consumption Value by Application (2019-2030)
- 8.3 Asia-Pacific Anti-spasmodic Drugs Market Size by Region
  - 8.3.1 Asia-Pacific Anti-spasmodic Drugs Consumption Value by Region (2019-2030)
  - 8.3.2 China Anti-spasmodic Drugs Market Size and Forecast (2019-2030)
  - 8.3.3 Japan Anti-spasmodic Drugs Market Size and Forecast (2019-2030)
  - 8.3.4 South Korea Anti-spasmodic Drugs Market Size and Forecast (2019-2030)
  - 8.3.5 India Anti-spasmodic Drugs Market Size and Forecast (2019-2030)
  - 8.3.6 Southeast Asia Anti-spasmodic Drugs Market Size and Forecast (2019-2030)
  - 8.3.7 Australia Anti-spasmodic Drugs Market Size and Forecast (2019-2030)

## **9 SOUTH AMERICA**

- 9.1 South America Anti-spasmodic Drugs Consumption Value by Type (2019-2030)
- 9.2 South America Anti-spasmodic Drugs Consumption Value by Application (2019-2030)
- 9.3 South America Anti-spasmodic Drugs Market Size by Country
  - 9.3.1 South America Anti-spasmodic Drugs Consumption Value by Country (2019-2030)
  - 9.3.2 Brazil Anti-spasmodic Drugs Market Size and Forecast (2019-2030)
  - 9.3.3 Argentina Anti-spasmodic Drugs Market Size and Forecast (2019-2030)

## **10 MIDDLE EAST & AFRICA**

- 10.1 Middle East & Africa Anti-spasmodic Drugs Consumption Value by Type

(2019-2030)

10.2 Middle East & Africa Anti-spasmodic Drugs Consumption Value by Application

(2019-2030)

10.3 Middle East & Africa Anti-spasmodic Drugs Market Size by Country

10.3.1 Middle East & Africa Anti-spasmodic Drugs Consumption Value by Country

(2019-2030)

10.3.2 Turkey Anti-spasmodic Drugs Market Size and Forecast (2019-2030)

10.3.3 Saudi Arabia Anti-spasmodic Drugs Market Size and Forecast (2019-2030)

10.3.4 UAE Anti-spasmodic Drugs Market Size and Forecast (2019-2030)

## **11 MARKET DYNAMICS**

11.1 Anti-spasmodic Drugs Market Drivers

11.2 Anti-spasmodic Drugs Market Restraints

11.3 Anti-spasmodic Drugs Trends Analysis

11.4 Porters Five Forces Analysis

11.4.1 Threat of New Entrants

11.4.2 Bargaining Power of Suppliers

11.4.3 Bargaining Power of Buyers

11.4.4 Threat of Substitutes

11.4.5 Competitive Rivalry

## **12 INDUSTRY CHAIN ANALYSIS**

12.1 Anti-spasmodic Drugs Industry Chain

12.2 Anti-spasmodic Drugs Upstream Analysis

12.3 Anti-spasmodic Drugs Midstream Analysis

12.4 Anti-spasmodic Drugs Downstream Analysis

## **13 RESEARCH FINDINGS AND CONCLUSION**

## **14 APPENDIX**

14.1 Methodology

14.2 Research Process and Data Source

14.3 Disclaimer

## List Of Tables

### LIST OF TABLES

Table 1. Global Anti-spasmodic Drugs Consumption Value by Type, (USD Million), 2019 & 2023 & 2030

Table 2. Global Anti-spasmodic Drugs Consumption Value by Application, (USD Million), 2019 & 2023 & 2030

Table 3. Global Anti-spasmodic Drugs Consumption Value by Region (2019-2024) & (USD Million)

Table 4. Global Anti-spasmodic Drugs Consumption Value by Region (2025-2030) & (USD Million)

Table 5. Pfizer Company Information, Head Office, and Major Competitors

Table 6. Pfizer Major Business

Table 7. Pfizer Anti-spasmodic Drugs Product and Solutions

Table 8. Pfizer Anti-spasmodic Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 9. Pfizer Recent Developments and Future Plans

Table 10. Allergan Company Information, Head Office, and Major Competitors

Table 11. Allergan Major Business

Table 12. Allergan Anti-spasmodic Drugs Product and Solutions

Table 13. Allergan Anti-spasmodic Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 14. Allergan Recent Developments and Future Plans

Table 15. Ipsen Company Information, Head Office, and Major Competitors

Table 16. Ipsen Major Business

Table 17. Ipsen Anti-spasmodic Drugs Product and Solutions

Table 18. Ipsen Anti-spasmodic Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 19. Ipsen Recent Developments and Future Plans

Table 20. Teva Pharmaceuticals Company Information, Head Office, and Major Competitors

Table 21. Teva Pharmaceuticals Major Business

Table 22. Teva Pharmaceuticals Anti-spasmodic Drugs Product and Solutions

Table 23. Teva Pharmaceuticals Anti-spasmodic Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 24. Teva Pharmaceuticals Recent Developments and Future Plans

Table 25. Novartis Company Information, Head Office, and Major Competitors

Table 26. Novartis Major Business



Table 27. Novartis Anti-spasmodic Drugs Product and Solutions

Table 28. Novartis Anti-spasmodic Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 29. Novartis Recent Developments and Future Plans

Table 30. Johnson & Johnson Company Information, Head Office, and Major Competitors

Table 31. Johnson & Johnson Major Business

Table 32. Johnson & Johnson Anti-spasmodic Drugs Product and Solutions

Table 33. Johnson & Johnson Anti-spasmodic Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 34. Johnson & Johnson Recent Developments and Future Plans

Table 35. Takeda Pharmaceutical Company Information, Head Office, and Major Competitors

Table 36. Takeda Pharmaceutical Major Business

Table 37. Takeda Pharmaceutical Anti-spasmodic Drugs Product and Solutions

Table 38. Takeda Pharmaceutical Anti-spasmodic Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 39. Takeda Pharmaceutical Recent Developments and Future Plans

Table 40. Sun Pharmaceutical Industries Company Information, Head Office, and Major Competitors

Table 41. Sun Pharmaceutical Industries Major Business

Table 42. Sun Pharmaceutical Industries Anti-spasmodic Drugs Product and Solutions

Table 43. Sun Pharmaceutical Industries Anti-spasmodic Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 44. Sun Pharmaceutical Industries Recent Developments and Future Plans

Table 45. Merz Pharma Company Information, Head Office, and Major Competitors

Table 46. Merz Pharma Major Business

Table 47. Merz Pharma Anti-spasmodic Drugs Product and Solutions

Table 48. Merz Pharma Anti-spasmodic Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 49. Merz Pharma Recent Developments and Future Plans

Table 50. Mylan Company Information, Head Office, and Major Competitors

Table 51. Mylan Major Business

Table 52. Mylan Anti-spasmodic Drugs Product and Solutions

Table 53. Mylan Anti-spasmodic Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 54. Mylan Recent Developments and Future Plans

Table 55. Fresenius Kabi Company Information, Head Office, and Major Competitors

Table 56. Fresenius Kabi Major Business

- Table 57. Fresenius Kabi Anti-spasmodic Drugs Product and Solutions
- Table 58. Fresenius Kabi Anti-spasmodic Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 59. Fresenius Kabi Recent Developments and Future Plans
- Table 60. Endo International Company Information, Head Office, and Major Competitors
- Table 61. Endo International Major Business
- Table 62. Endo International Anti-spasmodic Drugs Product and Solutions
- Table 63. Endo International Anti-spasmodic Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 64. Endo International Recent Developments and Future Plans
- Table 65. Daewoong Pharmaceutical Company Information, Head Office, and Major Competitors
- Table 66. Daewoong Pharmaceutical Major Business
- Table 67. Daewoong Pharmaceutical Anti-spasmodic Drugs Product and Solutions
- Table 68. Daewoong Pharmaceutical Anti-spasmodic Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 69. Daewoong Pharmaceutical Recent Developments and Future Plans
- Table 70. Acorda Therapeutics Company Information, Head Office, and Major Competitors
- Table 71. Acorda Therapeutics Major Business
- Table 72. Acorda Therapeutics Anti-spasmodic Drugs Product and Solutions
- Table 73. Acorda Therapeutics Anti-spasmodic Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 74. Acorda Therapeutics Recent Developments and Future Plans
- Table 75. SteriMax Company Information, Head Office, and Major Competitors
- Table 76. SteriMax Major Business
- Table 77. SteriMax Anti-spasmodic Drugs Product and Solutions
- Table 78. SteriMax Anti-spasmodic Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 79. SteriMax Recent Developments and Future Plans
- Table 80. Emcure Pharmaceuticals Company Information, Head Office, and Major Competitors
- Table 81. Emcure Pharmaceuticals Major Business
- Table 82. Emcure Pharmaceuticals Anti-spasmodic Drugs Product and Solutions
- Table 83. Emcure Pharmaceuticals Anti-spasmodic Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 84. Emcure Pharmaceuticals Recent Developments and Future Plans
- Table 85. Sawai Pharmaceutical Company Information, Head Office, and Major Competitors



- Table 86. Sawai Pharmaceutical Major Business
- Table 87. Sawai Pharmaceutical Anti-spasmodic Drugs Product and Solutions
- Table 88. Sawai Pharmaceutical Anti-spasmodic Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 89. Sawai Pharmaceutical Recent Developments and Future Plans
- Table 90. Orient Pharma Company Information, Head Office, and Major Competitors
- Table 91. Orient Pharma Major Business
- Table 92. Orient Pharma Anti-spasmodic Drugs Product and Solutions
- Table 93. Orient Pharma Anti-spasmodic Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 94. Orient Pharma Recent Developments and Future Plans
- Table 95. Global Anti-spasmodic Drugs Revenue (USD Million) by Players (2019-2024)
- Table 96. Global Anti-spasmodic Drugs Revenue Share by Players (2019-2024)
- Table 97. Breakdown of Anti-spasmodic Drugs by Company Type (Tier 1, Tier 2, and Tier 3)
- Table 98. Market Position of Players in Anti-spasmodic Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
- Table 99. Head Office of Key Anti-spasmodic Drugs Players
- Table 100. Anti-spasmodic Drugs Market: Company Product Type Footprint
- Table 101. Anti-spasmodic Drugs Market: Company Product Application Footprint
- Table 102. Anti-spasmodic Drugs New Market Entrants and Barriers to Market Entry
- Table 103. Anti-spasmodic Drugs Mergers, Acquisition, Agreements, and Collaborations
- Table 104. Global Anti-spasmodic Drugs Consumption Value (USD Million) by Type (2019-2024)
- Table 105. Global Anti-spasmodic Drugs Consumption Value Share by Type (2019-2024)
- Table 106. Global Anti-spasmodic Drugs Consumption Value Forecast by Type (2025-2030)
- Table 107. Global Anti-spasmodic Drugs Consumption Value by Application (2019-2024)
- Table 108. Global Anti-spasmodic Drugs Consumption Value Forecast by Application (2025-2030)
- Table 109. North America Anti-spasmodic Drugs Consumption Value by Type (2019-2024) & (USD Million)
- Table 110. North America Anti-spasmodic Drugs Consumption Value by Type (2025-2030) & (USD Million)
- Table 111. North America Anti-spasmodic Drugs Consumption Value by Application (2019-2024) & (USD Million)
- Table 112. North America Anti-spasmodic Drugs Consumption Value by Application

(2025-2030) & (USD Million)

Table 113. North America Anti-spasmodic Drugs Consumption Value by Country (2019-2024) & (USD Million)

Table 114. North America Anti-spasmodic Drugs Consumption Value by Country (2025-2030) & (USD Million)

Table 115. Europe Anti-spasmodic Drugs Consumption Value by Type (2019-2024) & (USD Million)

Table 116. Europe Anti-spasmodic Drugs Consumption Value by Type (2025-2030) & (USD Million)

Table 117. Europe Anti-spasmodic Drugs Consumption Value by Application (2019-2024) & (USD Million)

Table 118. Europe Anti-spasmodic Drugs Consumption Value by Application (2025-2030) & (USD Million)

Table 119. Europe Anti-spasmodic Drugs Consumption Value by Country (2019-2024) & (USD Million)

Table 120. Europe Anti-spasmodic Drugs Consumption Value by Country (2025-2030) & (USD Million)

Table 121. Asia-Pacific Anti-spasmodic Drugs Consumption Value by Type (2019-2024) & (USD Million)

Table 122. Asia-Pacific Anti-spasmodic Drugs Consumption Value by Type (2025-2030) & (USD Million)

Table 123. Asia-Pacific Anti-spasmodic Drugs Consumption Value by Application (2019-2024) & (USD Million)

Table 124. Asia-Pacific Anti-spasmodic Drugs Consumption Value by Application (2025-2030) & (USD Million)

Table 125. Asia-Pacific Anti-spasmodic Drugs Consumption Value by Region (2019-2024) & (USD Million)

Table 126. Asia-Pacific Anti-spasmodic Drugs Consumption Value by Region (2025-2030) & (USD Million)

Table 127. South America Anti-spasmodic Drugs Consumption Value by Type (2019-2024) & (USD Million)

Table 128. South America Anti-spasmodic Drugs Consumption Value by Type (2025-2030) & (USD Million)

Table 129. South America Anti-spasmodic Drugs Consumption Value by Application (2019-2024) & (USD Million)

Table 130. South America Anti-spasmodic Drugs Consumption Value by Application (2025-2030) & (USD Million)

Table 131. South America Anti-spasmodic Drugs Consumption Value by Country (2019-2024) & (USD Million)

Table 132. South America Anti-spasmodic Drugs Consumption Value by Country (2025-2030) & (USD Million)

Table 133. Middle East & Africa Anti-spasmodic Drugs Consumption Value by Type (2019-2024) & (USD Million)

Table 134. Middle East & Africa Anti-spasmodic Drugs Consumption Value by Type (2025-2030) & (USD Million)

Table 135. Middle East & Africa Anti-spasmodic Drugs Consumption Value by Application (2019-2024) & (USD Million)

Table 136. Middle East & Africa Anti-spasmodic Drugs Consumption Value by Application (2025-2030) & (USD Million)

Table 137. Middle East & Africa Anti-spasmodic Drugs Consumption Value by Country (2019-2024) & (USD Million)

Table 138. Middle East & Africa Anti-spasmodic Drugs Consumption Value by Country (2025-2030) & (USD Million)

Table 139. Anti-spasmodic Drugs Raw Material

Table 140. Key Suppliers of Anti-spasmodic Drugs Raw Materials

## List Of Figures

### LIST OF FIGURES

Figure 1. Anti-spasmodic Drugs Picture

Figure 2. Global Anti-spasmodic Drugs Consumption Value by Type, (USD Million), 2019 & 2023 & 2030

Figure 3. Global Anti-spasmodic Drugs Consumption Value Market Share by Type in 2023

Figure 4. Antimuscarinics

Figure 5. Smooth Muscle Relaxants

Figure 6. Global Anti-spasmodic Drugs Consumption Value by Type, (USD Million), 2019 & 2023 & 2030

Figure 7. Anti-spasmodic Drugs Consumption Value Market Share by Application in 2023

Figure 8. Offline Channel Picture

Figure 9. Online Channel Picture

Figure 10. Global Anti-spasmodic Drugs Consumption Value, (USD Million): 2019 & 2023 & 2030

Figure 11. Global Anti-spasmodic Drugs Consumption Value and Forecast (2019-2030) & (USD Million)

Figure 12. Global Market Anti-spasmodic Drugs Consumption Value (USD Million) Comparison by Region (2019 & 2023 & 2030)

Figure 13. Global Anti-spasmodic Drugs Consumption Value Market Share by Region (2019-2030)

Figure 14. Global Anti-spasmodic Drugs Consumption Value Market Share by Region in 2023

Figure 15. North America Anti-spasmodic Drugs Consumption Value (2019-2030) & (USD Million)

Figure 16. Europe Anti-spasmodic Drugs Consumption Value (2019-2030) & (USD Million)

Figure 17. Asia-Pacific Anti-spasmodic Drugs Consumption Value (2019-2030) & (USD Million)

Figure 18. South America Anti-spasmodic Drugs Consumption Value (2019-2030) & (USD Million)

Figure 19. Middle East and Africa Anti-spasmodic Drugs Consumption Value (2019-2030) & (USD Million)

Figure 20. Global Anti-spasmodic Drugs Revenue Share by Players in 2023

Figure 21. Anti-spasmodic Drugs Market Share by Company Type (Tier 1, Tier 2 and

Tier 3) in 2023

Figure 22. Global Top 3 Players Anti-spasmodic Drugs Market Share in 2023

Figure 23. Global Top 6 Players Anti-spasmodic Drugs Market Share in 2023

Figure 24. Global Anti-spasmodic Drugs Consumption Value Share by Type (2019-2024)

Figure 25. Global Anti-spasmodic Drugs Market Share Forecast by Type (2025-2030)

Figure 26. Global Anti-spasmodic Drugs Consumption Value Share by Application (2019-2024)

Figure 27. Global Anti-spasmodic Drugs Market Share Forecast by Application (2025-2030)

Figure 28. North America Anti-spasmodic Drugs Consumption Value Market Share by Type (2019-2030)

Figure 29. North America Anti-spasmodic Drugs Consumption Value Market Share by Application (2019-2030)

Figure 30. North America Anti-spasmodic Drugs Consumption Value Market Share by Country (2019-2030)

Figure 31. United States Anti-spasmodic Drugs Consumption Value (2019-2030) & (USD Million)

Figure 32. Canada Anti-spasmodic Drugs Consumption Value (2019-2030) & (USD Million)

Figure 33. Mexico Anti-spasmodic Drugs Consumption Value (2019-2030) & (USD Million)

Figure 34. Europe Anti-spasmodic Drugs Consumption Value Market Share by Type (2019-2030)

Figure 35. Europe Anti-spasmodic Drugs Consumption Value Market Share by Application (2019-2030)

Figure 36. Europe Anti-spasmodic Drugs Consumption Value Market Share by Country (2019-2030)

Figure 37. Germany Anti-spasmodic Drugs Consumption Value (2019-2030) & (USD Million)

Figure 38. France Anti-spasmodic Drugs Consumption Value (2019-2030) & (USD Million)

Figure 39. United Kingdom Anti-spasmodic Drugs Consumption Value (2019-2030) & (USD Million)

Figure 40. Russia Anti-spasmodic Drugs Consumption Value (2019-2030) & (USD Million)

Figure 41. Italy Anti-spasmodic Drugs Consumption Value (2019-2030) & (USD Million)

Figure 42. Asia-Pacific Anti-spasmodic Drugs Consumption Value Market Share by Type (2019-2030)

Figure 43. Asia-Pacific Anti-spasmodic Drugs Consumption Value Market Share by Application (2019-2030)

Figure 44. Asia-Pacific Anti-spasmodic Drugs Consumption Value Market Share by Region (2019-2030)

Figure 45. China Anti-spasmodic Drugs Consumption Value (2019-2030) & (USD Million)

Figure 46. Japan Anti-spasmodic Drugs Consumption Value (2019-2030) & (USD Million)

Figure 47. South Korea Anti-spasmodic Drugs Consumption Value (2019-2030) & (USD Million)

Figure 48. India Anti-spasmodic Drugs Consumption Value (2019-2030) & (USD Million)

Figure 49. Southeast Asia Anti-spasmodic Drugs Consumption Value (2019-2030) & (USD Million)

Figure 50. Australia Anti-spasmodic Drugs Consumption Value (2019-2030) & (USD Million)

Figure 51. South America Anti-spasmodic Drugs Consumption Value Market Share by Type (2019-2030)

Figure 52. South America Anti-spasmodic Drugs Consumption Value Market Share by Application (2019-2030)

Figure 53. South America Anti-spasmodic Drugs Consumption Value Market Share by Country (2019-2030)

Figure 54. Brazil Anti-spasmodic Drugs Consumption Value (2019-2030) & (USD Million)

Figure 55. Argentina Anti-spasmodic Drugs Consumption Value (2019-2030) & (USD Million)

Figure 56. Middle East and Africa Anti-spasmodic Drugs Consumption Value Market Share by Type (2019-2030)

Figure 57. Middle East and Africa Anti-spasmodic Drugs Consumption Value Market Share by Application (2019-2030)

Figure 58. Middle East and Africa Anti-spasmodic Drugs Consumption Value Market Share by Country (2019-2030)

Figure 59. Turkey Anti-spasmodic Drugs Consumption Value (2019-2030) & (USD Million)

Figure 60. Saudi Arabia Anti-spasmodic Drugs Consumption Value (2019-2030) & (USD Million)

Figure 61. UAE Anti-spasmodic Drugs Consumption Value (2019-2030) & (USD Million)

Figure 62. Anti-spasmodic Drugs Market Drivers

Figure 63. Anti-spasmodic Drugs Market Restraints

Figure 64. Anti-spasmodic Drugs Market Trends



Figure 65. Porters Five Forces Analysis

Figure 66. Manufacturing Cost Structure Analysis of Anti-spasmodic Drugs in 2023

Figure 67. Manufacturing Process Analysis of Anti-spasmodic Drugs

Figure 68. Anti-spasmodic Drugs Industrial Chain

Figure 69. Methodology

Figure 70. Research Process and Data Source

## I would like to order

Product name: Global Anti-spasmodic Drugs Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Product link: <https://marketpublishers.com/r/G604324FEF85EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G604324FEF85EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



